Page last updated: 2024-12-07

n-(2-carboxyphenyl)phenoxyacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-carboxyphenyl)phenoxyacetamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99325
CHEMBL ID383582
SCHEMBL ID6032429
MeSH IDM0061202

Synonyms (34)

Synonym
18704-92-2
nsc211863
nsc-211863
MAYBRIDGE1_003446 ,
OPREA1_180670
AKOS000157502
HMS551E14
2-[(2-phenoxyacetyl)amino]benzoic acid
n-(2-phenoxyacetyl)anthranilic acid
2-(2-phenoxyacetamido)benzoic acid
CHEMBL383582
n-(2-carboxyphenyl)phenoxyacetamide
benzoic acid, 2-((phenoxyacetyl)amino)-
nsc 211863
unii-9aa4tsx1ye
9aa4tsx1ye ,
RKNMVALGNSLQQL-UHFFFAOYSA-N
2-(phenoxyacetamido)benzoic acid
SCHEMBL6032429
DTXSID50171976
2-(phenoxyacetylamino)benzoic acid
Z54337113
JS-3004
2-(2-phenoxyacetamido)benzoicacid
2-((phenoxyacetyl)amino)benzoic acid
n-(2-carboxyphenyl)-phenoxyacetamide
benzoic acid, 2-((2-phenoxyacetyl)amino)-
anthranilic acid, n-(phenoxyacetyl)-
2-(phenoxymethylcarbonylamino)benzoic acid
2-((2-phenoxyacetyl)amino)benzoic acid
n-(phenoxyacetyl)anthranilic acid
EN300-124242
CS-0225550
mfcd00663160
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID387342Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO-K1 cells at 25 uM2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.
AID387343Displacement of [3H]nicotinic acid from human GPR109A receptor expressed in CHO-K1 cells at 2.5 uM2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.
AID1872608Inhibition of recombinant human DHODH at 10 uM using dihydroorotate as substrate and UQ0 as co-substrate by DCIP dye based analysis relative to control2022European journal of medicinal chemistry, Mar-15, Volume: 232Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
AID286270Inhibition of HCV 1b BK NS5B delta21 RNA polymerase expressed in Escherichia coli2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase.
AID257050Inhibition of recombinant human AKR1C3 at 50 uM2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]